SEC Form 4 · accession 0001203311-19-000008
SEATTLE GENETICS INC /WA · SGEN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Vaughn B Himes
Officer — Chief Technical Officer
Period of report
Mar 8, 2019
Accepted (ET)
Mar 12, 2019 · 7:31 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001060736
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Mar 8, 2019 | M | 8,000 | $12.00 | A | 185,329 | D | |
| Common StockF3,F1 | Mar 8, 2019 | S | 4,657 | $68.48 | D | 180,672 | D | |
| Common StockF4,F1 | Mar 8, 2019 | S | 3,343 | $69.05 | D | 177,329 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Non-Qualified Stock Option (right to buy)F5 | $12.00 | Mar 8, 2019 | M | 8,000 | D | — | Aug 27, 2020 | Common Stock | 8,000 | 28,498 | D |
Explanation of responses
- F1Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting and 214 shares acquired under the Amended and Restated 2000 Employee Stock Purchase Plan on January 31, 2019.
- F2The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.
- F3Reflects sales of common stock executed in multiple transactions at prices ranging from $67.95 to $68.94. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
- F4Reflects sales of common stock executed in multiple transactions at prices ranging from $68.95 to $69.10. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
- F5Shares vested at a rate of 25% on 8/27/11 and monthly thereafter until all the shares were fully vested on 8/27/14.